Vertex Pharmaceuticals Inc. Files SEC Form 4 with Information on Director, Officer, or Owner Transactions

Strategic Insights -

U.S. Securities and Exchange Commission (SEC) filing by Vertex Pharmaceuticals Inc. reveals details about transactions involving directors, officers, or owners of more than 10% of the company's stock. The filing, submitted on July 7, 2015, discloses information on purchases and sales of equity securities. As a publicly-traded company, Vertex Pharmaceuticals Inc. is required to submit such filings to the SEC. The filing contains relationship information about the reporting person and their transactions.

Key Takeaways:

  • The SEC filing, submitted on July 7, 2015, was posted on July 20, 2015, and contains one document.
  • The SIC code for Vertex Pharmaceuticals Inc. is 2834, indicating Pharmaceutical Preparations.
  • The company's contact information is 50 NORTHERN AVENUE, BOSTON MA 02210, with a phone number of 6173416393.
  • The filing requires directors, officers, or owners of more than 10% of a class of equity securities registered under Section 12 of the '34 Act to submit a statement of ownership.
  • The forms (Form 3 and Form 4) contain information on the reporting person's relationship to the company and on purchases and sales of equity securities.
  • The Annual Statement of beneficial ownership of securities is on Form 5.

Statistics:

  • One document was filed with the SEC on July 7, 2015.
  • The SIC code for Vertex Pharmaceuticals Inc. is 2834.
  • The company's contact information includes a address of 50 NORTHERN AVENUE, BOSTON MA 02210 and a phone number of 6173416393.
  • The SEC filing requires more than 10% of equity securities holders to submit a statement, including purchases and sales.

Sources:

  • NewsRx LLC 2015, "Vertex Pharmaceuticals Inc. Files SEC Form 4 with Information on Director, Officer, or Owner Transactions"
  • U.S. Securities and Exchange Commission (SEC) - Form 4
  • NewsRx LLC 2015, (c) 2015, NewsRx LLC